IL21 and neoplasm: More recently, GPC3-CAR-T cells were engineered to co-express IL-21 and CXCL9, which, alongside blockade of the checkpoint inhibitor PD-1, were shown to offer a combo of increased cytokine secretion, proliferation, chemotaxis, and overall ameliorated anti-tumor activity [58].